From what 2 stock analysts predict, the share price for Ginkgo Bioworks Holdings, Inc. (DNA) might increase by 5.9% in the next year. This is based on a 12-month average estimation for DNA. Price targets go from $7 to $10. The majority of stock analysts believe DNA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assigned DNA 0 buy ratings, 0 hold ratings, and 2 sell ratings. This means that analysts expect Ginkgo Bioworks Holdings, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DNA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DNA.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Brendan Smith TD Cowen | Buy | $10 | Maintains | Sep 20, 2024 |
Mark Massaro BTIG | Sell | $7 | Maintains | Aug 23, 2024 |
Matthew Sykes Goldman Sachs | Sell | $0.3 | Maintains | Jul 9, 2024 |
Mark Massaro BTIG | Sell | $0.2 | Maintains | Jun 26, 2024 |
Mark Massaro BTIG | Sell | Downgrade | May 15, 2024 | |
Tejas Savant Morgan Stanley | Equal-Weight | $1 | Maintains | May 15, 2024 |
Matt Larew William Blair | Underperform | Downgrade | May 10, 2024 | |
Steven Mah TD Cowen | Outperform | $3 | Maintains | Mar 1, 2024 |
Matthew Sykes Goldman Sachs | Sell | $1.1 | Maintains | Jan 23, 2024 |
Matthew Sykes Goldman Sachs | Sell | $1.1 | Maintains | Jan 22, 2024 |
Rahul Sarugaser Raymond James | Market Perform | $2.5 | Downgrade | Nov 15, 2023 |
Rahul Sarugaser Raymond James | Market Perform | $2.5 | Downgrade | Nov 14, 2023 |
Mark Massaro BTIG | Neutral | Downgrade | Nov 9, 2023 | |
Matthew Sykes Goldman Sachs | Sell | $1.25 | Maintains | Jun 5, 2023 |
Matthew Sykes Goldman Sachs | Sell | $1.25 | Downgrade | Jun 2, 2023 |
Matt Larew William Blair | Market Perform | Downgrade | May 11, 2023 | |
Gaurav Goparaju Berenberg | Buy | $6 | Initiates | Nov 29, 2022 |
Tejas Savant Morgan Stanley | Equal-Weight | $5 | Initiates | Oct 4, 2022 |
Mark Massaro BTIG | Buy | $6 | Maintains | Aug 16, 2022 |
Rahul Sarugaser Raymond James | Outperform | $14.5 | Maintains | Aug 16, 2022 |
When did it IPO
2021
Staff Count
1,218
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jason Kelly
Market Cap
$435.7M
In 2023, DNA generated $251.5M in revenue, which was a decrease of -47.36% from the previous year. This can be seen as a signal that DNA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Ginkgo Bioworks will host a Q&A session on November 12, 2024, at 5:30 p.m. ET to discuss its Q3 2024 business performance. Details will be on their investor relations website.
Why It Matters - The upcoming presentation on Ginkgo Bioworks' Q3 performance will provide insights into its financial health and strategic direction, impacting investor sentiment and stock valuation.
Summary - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63, down 1.55% from the previous trading day.
Why It Matters - The decline in Ginkgo Bioworks' stock price signals potential investor concern, which might affect future trading and investment strategies.
Summary - Ginkgo Bioworks' stock fell 5.04% to $7.92 with a trading volume of 354,386 shares and a price fluctuation of 6.59%. Turnover rate was 0.64%.
Why It Matters - Ginkgo Bioworks' 5.04% stock drop and high volatility indicate potential investor concerns, impacting market sentiment and signaling possible risks in its financial health.
Summary - Virica and Ginkgo have formed a strategic partnership to improve the productivity of adeno-associated virus (AAV) gene therapy manufacturing platforms.
Why It Matters - The partnership between Virica and Ginkgo could lead to improved AAV gene therapy production, potentially increasing market competitiveness and influencing biotech stock valuations.
Summary - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.70, down 0.77% from the previous trading day.
Why It Matters - Ginkgo Bioworks' recent stock decline indicates potential volatility, impacting investor sentiment and future trading strategies.
Summary - Ginkgo Bioworks (NYSE: DNA) announced a partnership with NOVUS International to develop advanced feed additives for the animal agriculture industry.
Why It Matters - Ginkgo Bioworks' partnership with NOVUS International indicates growth potential in the animal agriculture sector, potentially enhancing revenue and market position for both companies.